398 research outputs found
Approaching Conformality with Ten Flavors
We present first results for lattice simulations, on a single volume, of the
low-lying spectrum of an SU(3) Yang-Mills gauge theory with ten light fermions
in the fundamental representation. Fits to the fermion mass dependence of
various observables are found to be globally consistent with the hypothesis
that this theory is within or just outside the strongly-coupled edge of the
conformal window, with mass anomalous dimension consistent with 1 over the
range of scales simulated. We stress that we cannot rule out the possibility of
spontaneous chiral-symmetry breaking at scales well below our infrared cutoff.
We discuss important systematic effects, including finite-volume corrections,
and consider directions for future improvement.Comment: 7 pages, 3 figures. Submitted to Physical Review Letters. v2:
corrected global fits. v3: corrected estimation of confidence interval
WW Scattering Parameters via Pseudoscalar Phase Shifts
Using domain-wall lattice simulations, we study pseudoscalar-pseudoscalar
scattering in the maximal isospin channel for an SU(3) gauge theory with two
and six fermion flavors in the fundamental representation. This calculation of
the S-wave scattering length is related to the next-to-leading order
corrections to WW scattering through the low-energy coefficients of the chiral
Lagrangian. While two and six flavor scattering lengths are similar for a fixed
ratio of the pseudoscalar mass to its decay constant, six-flavor scattering
shows a somewhat less repulsive next-to-leading order interaction than its
two-flavor counterpart. Estimates are made for the WW scattering parameters and
the plausibility of detection is discussed.Comment: 8 pages, 6 figure
Application of quasi-Monte Carlo methods to PDEs with random coefficients -- an overview and tutorial
This article provides a high-level overview of some recent works on the
application of quasi-Monte Carlo (QMC) methods to PDEs with random
coefficients. It is based on an in-depth survey of a similar title by the same
authors, with an accompanying software package which is also briefly discussed
here. Embedded in this article is a step-by-step tutorial of the required
analysis for the setting known as the uniform case with first order QMC rules.
The aim of this article is to provide an easy entry point for QMC experts
wanting to start research in this direction and for PDE analysts and
practitioners wanting to tap into contemporary QMC theory and methods.Comment: arXiv admin note: text overlap with arXiv:1606.0661
Are chimpanzees really so poor at understanding imperative pointing? Some new data and an alternative view of canine and ape social cognition
There is considerable interest in comparative research on different species’ abilities to respond to human communicative cues such as gaze and pointing. It has been reported that some canines perform significantly better than monkeys and apes on tasks requiring the comprehension of either declarative or imperative pointing and these differences have been attributed to domestication in dogs. Here we tested a sample of chimpanzees on a task requiring comprehension of an imperative request and show that, though there are considerable individual differences, the performance by the apes rival those reported in pet dogs. We suggest that small differences in methodology can have a pronounced influence on performance on these types of tasks. We further suggest that basic differences in subject sampling, subject recruitment and rearing experiences have resulted in a skewed representation of canine abilities compared to those of monkeys and apes
A Complete Spectroscopic Survey of the Milky Way Satellite Segue 1: The Darkest Galaxy
We present the results of a comprehensive Keck/DEIMOS spectroscopic survey of
the ultra-faint Milky Way satellite galaxy Segue 1. We have obtained velocity
measurements for 98.2% of the stars within 67 pc (10 arcmin, or 2.3 half-light
radii) of the center of Segue 1 that have colors and magnitudes consistent with
membership, down to a magnitude limit of r=21.7. Based on photometric,
kinematic, and metallicity information, we identify 71 stars as probable Segue
1 members, including some as far out as 87 pc. After correcting for the
influence of binary stars using repeated velocity measurements, we determine a
velocity dispersion of 3.7^{+1.4}_{-1.1} km/s, with a corresponding mass within
the half-light radius of 5.8^{+8.2}_{-3.1} x 10^5 Msun. The stellar kinematics
of Segue 1 require very high mass-to-light ratios unless the system is far from
dynamical equilibrium, even if the period distribution of unresolved binary
stars is skewed toward implausibly short periods. With a total luminosity less
than that of a single bright red giant and a V-band mass-to-light ratio of 3400
Msun/Lsun, Segue 1 is the darkest galaxy currently known. We critically
re-examine recent claims that Segue 1 is a tidally disrupting star cluster and
that kinematic samples are contaminated by the Sagittarius stream. The
extremely low metallicities ([Fe/H] < -3) of two Segue 1 stars and the large
metallicity spread among the members demonstrate conclusively that Segue 1 is a
dwarf galaxy, and we find no evidence in favor of tidal effects. We also show
that contamination by the Sagittarius stream has been overestimated. Segue 1
has the highest measured dark matter density of any known galaxy and will
therefore be a prime testing ground for dark matter physics and galaxy
formation on small scales.Comment: 24 pages, 4 tables, 11 figures (10 in color). Submitted for
publication in ApJ. V3 revised according to comments from the refere
Infected Cell Killing by HIV-1 Protease Promotes NF-κB Dependent HIV-1 Replication
Acute HIV-1 infection of CD4 T cells often results in apoptotic death of infected cells, yet it is unclear what evolutionary advantage this offers to HIV-1. Given the independent observations that acute T cell HIV-1 infection results in (1) NF-κB activation, (2) caspase 8 dependent apoptosis, and that (3) caspase 8 directly activates NF-κB, we questioned whether these three events might be interrelated. We first show that HIV-1 infected T cell apoptosis, NF-κB activation, and caspase 8 cleavage by HIV-1 protease are coincident. Next we show that HIV-1 protease not only cleaves procaspase 8, producing Casp8p41, but also independently stimulates NF-κB activity. Finally, we demonstrate that the HIV protease cleavage of caspase 8 is necessary for optimal NF-κB activation and that the HIV-1 protease specific cleavage fragment Casp8p41 is sufficient to stimulate HIV-1 replication through NF-κB dependent HIV-LTR activation both in vitro as well as in cells from HIV infected donors. Consequently, the molecular events which promote death of HIV-1 infected T cells function dually to promote HIV-1 replication, thereby favoring the propagation and survival of HIV-1
Assessment of the Sheffield Support Snood, an innovative cervical orthosis designed for people affected by neck weakness
The aim of this study was to quantify the biomechanical features of the Sheffield Support Snood (SSS), a cervical orthosis specifically designed for patients with neck weakness. The orthosis is designed to be adaptable to a patient’s level of functional limitation using adjustable removable supports, which contribute support and restrict movement only in desired anatomical planes.
Methods: The SSS was evaluated along with two commercially available orthoses, the Vista and Headmaster. The orthoses were compared in a series of flexion, extension, axial-rotation and lateral bending movements. Characterisation was performed with twelve healthy subjects with and without the orthoses. Two Inertial-Magneto sensors, placed on forehead and sternum, were used to quantify the neck range of motion (ROM).
Findings: In its less rigid configuration, the SSS was effective in limiting movements only in the desired planes, preserving free movement in other planes, whereas the headmaster was only effective in limiting the flexion. The percentage of ROM achieved with the SSS in its rigid configuration is equivalent (P > 0.05, effect size < 0.4) to that achieved with the Vista, both in trials performed reaching the maximum amplitude (ROM reduction: 25%-34% vs 24%-47%) and at maximum speed (ROM reduction: 24%-29% vs 25%-43%).
Interpretation: The SSS is effectively adaptable to different tasks and in its rigid configuration offers a support comparable to the Vista, although it has a less bulky structure. The chosen method is suitable for the assessment of ROM movements while wearing neck orthoses and easily translatable in a clinical context
Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area
This study advances the clinical development of the RTS,S/AS01B candidate malaria vaccine to malaria endemic populations. As a primary objective it compares the safety and reactogenicity of RTS,S/AS01B to the more extensively evaluated RTS,S/AS02A vaccine.A Phase IIb, single centre, double-blind, controlled trial of 6 months duration with a subsequent 6 month single-blind follow-up conducted in Kisumu West District, Kenya between August 2005 and August 2006. 255 healthy adults aged 18 to 35 years were randomized (1ratio1ratio1) to receive 3 doses of RTS,S/AS02A, RTS,S/AS01B or rabies vaccine (Rabipur; Chiron Behring GmbH) at months 0, 1, 2. The primary objective was the occurrence of severe (grade 3) solicited or unsolicited general (i.e. systemic) adverse events (AEs) during 7 days follow up after each vaccination.Both candidate vaccines had a good safety profile and were well tolerated. One grade 3 systemic AE occurred within 7 days of vaccination (RTS,S/AS01B group). No unsolicited AEs or SAEs were related to vaccine. A marked increase in anti-CS antibody GMTs was observed post Dose 2 of both RTS,S/AS01B (31.6 EU/mL [95% CI: 23.9 to 41.6]) and RTS,S/AS02A (16.7 EU/mL [95% CI: 12.9 to 21.7]). A further increase was observed post Dose 3 in both the RTS,S/AS01B (41.4 EU/mL [95% CI: 31.7 to 54.2]) and RTS,S/AS02A (21.4 EU/mL [95% CI: 16.0 to 28.7]) groups. Anti-CS antibody GMTs were significantly greater with RTS,S/AS01B compared to RTS,S/AS02A at all time points post Dose 2 and Dose 3. Both candidate vaccines produced strong anti-HBs responses. Vaccine efficacy in the RTS,S/AS01B group was 29.5% (95% CI: -15.4 to 56.9, p = 0.164) and in the RTS,S/AS02A group 31.7% (95% CI: -11.6 to 58.2, p = 0.128).Both candidate malaria vaccines were well tolerated over a 12 month surveillance period. A more favorable immunogenicity profile was observed with RTS,S/AS01B than with RTS,S/AS02A.Clinicaltrials.gov NCT00197054
Coupling Optical and Electrical Measurements in Artificial Membranes: Lateral Diffusion of Lipids and Channel Forming Peptides in Planar Bilayers
Planar lipid bilayers (PLB) were prepared by the Montal-Mueller technique in a FRAP system designed to simultaneously measure conductivity across, and lateral diffusion of, the bilayer. In the first stage of the project the FRAP system was used to characterise the lateral dynamics of bilayer lipids with regards to phospholipid composition (headgroup, chain unsaturation etc.), presence of cholesterol and the effect of divalent cations on negatively-charged bilayers. In the second stage of the project, lateral diffusion of two fluorescently-labelled voltage-dependent pore-forming peptides (alamethicin and S4s from Shaker K(+) channel) was determined at rest and in the conducting state. This study demonstrates the feasibility of such experiments with PLBs, amenable to physical constraints, and thus offers new opportunities for systematic studies of structure-function relationships in membrane-associating molecules
Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A
Contains fulltext :
79496.pdf (publisher's version ) (Open Access)BACKGROUND: This Phase 1/2a study evaluated the safety, immunogenicity, and efficacy of an experimental malaria vaccine comprised of the recombinant Plasmodium falciparum protein apical membrane antigen-1 (AMA-1) representing the 3D7 allele formulated with either the AS01B or AS02A Adjuvant Systems. METHODOLOGY/PRINCIPAL FINDINGS: After a preliminary safety evaluation of low dose AMA-1/AS01B (10 microg/0.5 mL) in 5 adults, 30 malaria-naive adults were randomly allocated to receive full dose (50 microg/0.5 mL) of AMA-1/AS01B (n = 15) or AMA-1/AS02A (n = 15), followed by a malaria challenge. All vaccinations were administered intramuscularly on a 0-, 1-, 2-month schedule. All volunteers experienced transient injection site erythema, swelling and pain. Two weeks post-third vaccination, anti-AMA-1 Geometric Mean Antibody Concentrations (GMCs) with 95% Confidence Intervals (CIs) were high: low dose AMA-1/AS01B 196 microg/mL (103-371 microg/mL), full dose AMA-1/AS01B 279 microg/mL (210-369 microg/mL) and full dose AMA-1/AS02A 216 microg/mL (169-276 microg/mL) with no significant difference among the 3 groups. The three vaccine formulations elicited equivalent functional antibody responses, as measured by growth inhibition assay (GIA), against homologous but not against heterologous (FVO) parasites as well as demonstrable interferon-gamma (IFN-gamma) responses. To assess efficacy, volunteers were challenged with P. falciparum-infected mosquitoes, and all became parasitemic, with no significant difference in the prepatent period by either light microscopy or quantitative polymerase chain reaction (qPCR). However, a small but significant reduction of parasitemia in the AMA-1/AS02A group was seen with a statistical model employing qPCR measurements. SIGNIFICANCE: All three vaccine formulations were found to be safe and highly immunogenic. These immune responses did not translate into significant vaccine efficacy in malaria-naive adults employing a primary sporozoite challenge model, but encouragingly, estimation of parasite growth rates from qPCR data may suggest a partial biological effect of the vaccine. Further evaluation of the immunogenicity and efficacy of the AMA-1/AS02A formulation is ongoing in a malaria-experienced pediatric population in Mali. TRIAL REGISTRATION: www.clinicaltrials.gov NCT00385047
- …